Use of the XXXX -specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development.

@entity5 @entity1 @entity2 @entity23
UNASSIGNED: The European Organisation for Research and Treatment of @entity5 (EORTC) Quality of Life Questionnaire-Lung @entity5 13 (QLQ-LC13) covers 13 typical symptoms of @entity2 @entity1 and was the first module developed in conjunction with the EORTC core quality-of-life (QL) questionnaire. This review investigates how the module has been used and reported in @entity5 clinical trials in the 20 years since its publication. Thirty-six databases were searched with a prespecified algorithm. This search plus an additional hand search generated 770 hits, 240 of which were clinical studies. Two raters extracted data using a coding scheme. Analyses focused on the @entity23 ( @entity23 ). Of the 240 clinical studies that were identified using the LC13, 109 (45%) were @entity23 . More than half of the @entity23 were phase 3 trials (n   =   58). Twenty @entity23 considered QL as the primary endpoint, and 68 considered it as a secondary endpoint. QL results were addressed in the results section of the article (n   =   89) or in the abstract (n   =   92); and, in half of the articles, QL results were presented in the form of tables (n   =   53) or figures (n   =   43). Furthermore, QL results had an impact on the evaluation of the therapy that could be clearly demonstrated in the 47 @entity23 that yielded QL differences between treatment and control groups. The EORTC QLQ-LC13 fulfilled its mission to be used as a standard instrument in @entity2 clinical trials. An update of the LC13 is underway to keep up with new therapeutic trends and to ensure optimized and relevant QL assessment in future trials. @entity5 2015;121:4300-23.    2015 American @entity5 Society.
